Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SRRK with free AI briefings, catalyst countdowns, and dilution alerts.

SRRK · Scholar Rock Holding Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$413.6M Cash on Hand
16.3mo Cash Runway
24% Short Interest
$70.06 Analyst Target (16)
Follow SRRK by email Get an email when SRRK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SRRK, unsubscribe in one click. Privacy

📣 What SRRK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Apitegromab
FDA approved Sep 2026 · Isembyld
Spinal Muscular Atrophy Phase 3 · NCT05626855 Active not recruiting
Risdiplam Spinal Muscular Atrophy Phase 2 · NCT07047144 Recruiting
SRK-015 Spinal Muscular Atrophy Phase 2 · NCT03921528 Completed
anti-PD-(L)1 antibody therapy Cancer Phase 1 · NCT04291079 Completed
Linavonkibart (SRK-181) Cancer Phase 1 · NCT04291079 Completed
SRK-439 Healthy Phase 1 · NCT07444294 Recruiting

Also used in these trials (approved or third-party drugs, not SRRK's own candidates): Nusinersen, Tirzepatide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SRRK holds $413.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $76.1M/quarter from operations, an estimated runway of 16.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SRRK files for a raise →

👥 Who Owns SRRK

Insiders 20.4% Other 5%+ holders 7.8% Institutions (452 holders) 71.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 18,207,328 14.92% 2026-09-30
Invus Global Management, LLC
10% owner
Insider 10,825,013 8.87% 2025-12-11
Invus Public Equities, L.P. 5%+ holder (13G) 9,575,013 7.85% 2026-06-30
Blackrock Inc. Institution (13F) 9,558,524 7.83% 2026-09-30
Siren, L.L.C. Institution (13F) 9,375,013 7.68% 2026-09-30
Srinivas Akkaraju
Director · +4,310 options
Insider 7,131,508 5.85% 2026-10-23
Samsara BioCapital, LLC Institution (13F) 6,897,652 5.65% 2026-09-30
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 6,206,044 5.09% 2026-03-31
Orbis Allan Gray Ltd Institution (13F) 6,075,392 4.98% 2026-09-30
Wellington Management Group LLP Institution (13G, 5%+) 5,759,428 4.72% 2025-12-31
Vanguard Capital Management LLC Institution (13F) 4,805,259 3.94% 2026-09-30
Massachusetts Financial Services Co. Institution (13F) 4,655,936 3.82% 2026-09-30

Share count 122,004,478 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-26
filed 2026-10-27
AKKARAJU SRINIVAS
Purchase (P) 48,988 $41.59 6,380,517
2026-10-26
filed 2026-10-27
AKKARAJU SRINIVAS
Purchase (P) 97,982 $41.59 723,020
2026-10-23
filed 2026-10-27
AKKARAJU SRINIVAS
Purchase (P) 47,000 $41.31 6,331,029
2026-10-23
filed 2026-10-27
AKKARAJU SRINIVAS
Purchase (P) 94,000 $41.31 624,038
2026-10-23
filed 2026-10-27
AKKARAJU SRINIVAS
Purchase (P) 500 $41.82 6,331,529

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-09-11 ISEMBYLD BLA +6.9% -0.5% -12%
2026-03-03 — BLA -3.2% +1.9% +1.7%
2025-09-22 apitegromab BLA -10.4% +5.6% +25.7%

Browse all historical PDUFA outcomes →

Get the full SRRK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRRK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.